PF-06823859
Monoclonal antibody
Evidence outlook · registrational
Dermatomyositis: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2030-07-29.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Dermatomyositis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PF-06823859: this drug | Phase 3 | Monoclonal antibody | Interferon beta (IFN-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Descartes-08 | Phase 1/2 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow PF-06823859 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.